S&P 500   3,848.16 (+0.16%)
DOW   31,949.77 (+1.44%)
QQQ   305.47 (-1.04%)
AAPL   117.83 (-2.96%)
MSFT   230.36 (-0.54%)
FB   259.00 (-2.00%)
GOOGL   2,054.17 (-2.05%)
TSLA   580.15 (-2.98%)
AMZN   3,007.24 (+0.23%)
NVDA   473.24 (-5.06%)
BABA   228.54 (-2.29%)
CGC   31.38 (+0.67%)
GE   14.21 (+4.49%)
MU   86.64 (-2.58%)
NIO   36.32 (-4.70%)
AMD   75.81 (-3.45%)
T   30.35 (+2.46%)
F   12.62 (+2.85%)
ACB   9.75 (+1.56%)
DIS   200.61 (+5.59%)
BA   227.32 (+1.84%)
NFLX   505.70 (-2.07%)
PFE   34.79 (+1.16%)
S&P 500   3,848.16 (+0.16%)
DOW   31,949.77 (+1.44%)
QQQ   305.47 (-1.04%)
AAPL   117.83 (-2.96%)
MSFT   230.36 (-0.54%)
FB   259.00 (-2.00%)
GOOGL   2,054.17 (-2.05%)
TSLA   580.15 (-2.98%)
AMZN   3,007.24 (+0.23%)
NVDA   473.24 (-5.06%)
BABA   228.54 (-2.29%)
CGC   31.38 (+0.67%)
GE   14.21 (+4.49%)
MU   86.64 (-2.58%)
NIO   36.32 (-4.70%)
AMD   75.81 (-3.45%)
T   30.35 (+2.46%)
F   12.62 (+2.85%)
ACB   9.75 (+1.56%)
DIS   200.61 (+5.59%)
BA   227.32 (+1.84%)
NFLX   505.70 (-2.07%)
PFE   34.79 (+1.16%)
S&P 500   3,848.16 (+0.16%)
DOW   31,949.77 (+1.44%)
QQQ   305.47 (-1.04%)
AAPL   117.83 (-2.96%)
MSFT   230.36 (-0.54%)
FB   259.00 (-2.00%)
GOOGL   2,054.17 (-2.05%)
TSLA   580.15 (-2.98%)
AMZN   3,007.24 (+0.23%)
NVDA   473.24 (-5.06%)
BABA   228.54 (-2.29%)
CGC   31.38 (+0.67%)
GE   14.21 (+4.49%)
MU   86.64 (-2.58%)
NIO   36.32 (-4.70%)
AMD   75.81 (-3.45%)
T   30.35 (+2.46%)
F   12.62 (+2.85%)
ACB   9.75 (+1.56%)
DIS   200.61 (+5.59%)
BA   227.32 (+1.84%)
NFLX   505.70 (-2.07%)
PFE   34.79 (+1.16%)
S&P 500   3,848.16 (+0.16%)
DOW   31,949.77 (+1.44%)
QQQ   305.47 (-1.04%)
AAPL   117.83 (-2.96%)
MSFT   230.36 (-0.54%)
FB   259.00 (-2.00%)
GOOGL   2,054.17 (-2.05%)
TSLA   580.15 (-2.98%)
AMZN   3,007.24 (+0.23%)
NVDA   473.24 (-5.06%)
BABA   228.54 (-2.29%)
CGC   31.38 (+0.67%)
GE   14.21 (+4.49%)
MU   86.64 (-2.58%)
NIO   36.32 (-4.70%)
AMD   75.81 (-3.45%)
T   30.35 (+2.46%)
F   12.62 (+2.85%)
ACB   9.75 (+1.56%)
DIS   200.61 (+5.59%)
BA   227.32 (+1.84%)
NFLX   505.70 (-2.07%)
PFE   34.79 (+1.16%)
Log in
NYSE:RCUS

Arcus Biosciences Stock Forecast, Price & News

$31.10
-2.91 (-8.56 %)
(As of 03/8/2021 01:42 PM ET)
Add
Compare
Today's Range
$30.94
Now: $31.10
$33.96
50-Day Range
$31.66
MA: $36.33
$41.39
52-Week Range
$9.85
Now: $31.10
$42.36
Volume15,823 shs
Average Volume532,716 shs
Market Capitalization$2.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.26
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab (AB154), its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; license agreements with Taiho Pharmaceutical Co., Ltd and Abmuno Therapeutics LLC; and strategic relationship with WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was founded in 2015 and is based in Hayward, California.
Arcus Biosciences logo

Headlines

Affimed (AFMD) Catches Eye: Stock Jumps 8.8%
January 14, 2021 |  finance.yahoo.com
RCUS Jan 2021 25.000 call
December 26, 2020 |  au.finance.yahoo.com
RCUS Jan 2021 12.500 put
December 26, 2020 |  au.finance.yahoo.com
RCUS Jan 2021 30.000 put
December 25, 2020 |  au.finance.yahoo.com
Arcus Biosciences EPS beats by $0.62, beats on revenue
November 5, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone510-694-6200
Employees139
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15 million
Book Value$3.57 per share

Profitability

Net Income$-84,710,000.00
Net Margins-112.63%

Miscellaneous

Market Cap$2.20 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

61st out of 1,968 stocks

Pharmaceutical Preparations Industry

23rd out of 771 stocks

Analyst Opinion: 4.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
$31.10
-2.91 (-8.56 %)
(As of 03/8/2021 01:42 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RCUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions

Is Arcus Biosciences a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arcus Biosciences stock.
View analyst ratings for Arcus Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Arcus Biosciences?

Wall Street analysts have given Arcus Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arcus Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Arcus Biosciences' next earnings date?

Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Arcus Biosciences
.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) announced its quarterly earnings results on Tuesday, February, 23rd. The company reported ($0.82) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.74) by $0.08. Arcus Biosciences had a negative trailing twelve-month return on equity of 27.43% and a negative net margin of 112.63%.
View Arcus Biosciences' earnings history
.

How has Arcus Biosciences' stock price been impacted by Coronavirus?

Arcus Biosciences' stock was trading at $16.97 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RCUS stock has increased by 83.4% and is now trading at $31.12.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RCUS?

9 brokers have issued 12 month price objectives for Arcus Biosciences' shares. Their forecasts range from $34.00 to $70.00. On average, they anticipate Arcus Biosciences' stock price to reach $49.91 in the next twelve months. This suggests a possible upside of 60.4% from the stock's current price.
View analysts' price targets for Arcus Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Arcus Biosciences' key executives?

Arcus Biosciences' management team includes the following people:
  • Dr. Terry J. Rosen Ph.D., Co-Founder, Chairman & CEO (Age 61, Pay $341.2k)
  • Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 63, Pay $751.2k)
  • Ms. Jennifer Jarrett M.B.A., COO & Director (Age 50, Pay $33.93k)
  • Dr. William J. Grossman, Chief Medical Officer (Age 51, Pay $677.27k)
  • Mr. Robert C. Goeltz II, CFO & Principal Accounting Officer (Age 48)
  • Dr. Stephen Young Ph.D., VP of Technology (Age 52)
  • Ms. Katherine Bock, VP of Investor Relations & Corp. Strategy
  • Ms. Carolyn C. Tang, Gen. Counsel & Corp. Sec.
  • Ms. Yvonne Gehring, VP of HR & Operations
  • Dr. Jay P. Powers, Sr. VP of Drug Discovery (Age 55)

What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences CEO Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among Arcus Biosciences' employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Arcus Biosciences' key competitors?

What other stocks do shareholders of Arcus Biosciences own?

When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.01%), Victory Capital Management Inc. (1.74%), Northern Trust Corp (0.82%), JPMorgan Chase & Co. (0.77%), Candriam Luxembourg S.C.A. (0.63%) and Asymmetry Capital Management L.P. (0.54%). Company insiders that own Arcus Biosciences stock include Gilead Sciences Inc, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen and William Grossman.
View institutional ownership trends for Arcus Biosciences
.

Which institutional investors are selling Arcus Biosciences stock?

RCUS stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Dimensional Fund Advisors LP, Candriam Luxembourg S.C.A., Victory Capital Management Inc., Baker BROS. Advisors LP, Trexquant Investment LP, Credit Suisse AG, and Squarepoint Ops LLC.
View insider buying and selling activity for Arcus Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Arcus Biosciences stock?

RCUS stock was purchased by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., Great Lakes Advisors LLC, BlackRock Inc., JPMorgan Chase & Co., First Trust Advisors LP, Tudor Investment Corp Et Al, Principal Financial Group Inc., and Norges Bank. Company insiders that have bought Arcus Biosciences stock in the last two years include Gilead Sciences Inc, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, and William Grossman.
View insider buying and selling activity for Arcus Biosciences
or or view top insider-buying stocks.

How do I buy shares of Arcus Biosciences?

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $31.12.

How much money does Arcus Biosciences make?

Arcus Biosciences has a market capitalization of $2.21 billion and generates $15 million in revenue each year. The company earns $-84,710,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does Arcus Biosciences have?

Arcus Biosciences employs 139 workers across the globe.

What is Arcus Biosciences' official website?

The official website for Arcus Biosciences is www.arcusbio.com.

Where are Arcus Biosciences' headquarters?

Arcus Biosciences is headquartered at 3928 Point Eden Way, Hayward CA, 94545.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.